3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
Other hematologic neoplasm
2
CNS
2
Thoracic
1
Myeloid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Interventions
Carboplatin
352
pembrolizumab
327
Pemetrexed
250
Cisplatin
222
Paclitaxel
149
Nivolumab
139
durvalumab
134
osimertinib
112
Docetaxel
112
atezolizumab
109
Specimen Handling
91
Radiotherapy
89
Drug Therapy
87
Magnetic Resonance Spectroscopy
78
Etoposide
78
Radiosurgery
74
Gemcitabine
72
Ipilimumab
55
130-nm albumin-bound paclitaxel
54
Bevacizumab
53
cemiplimab
47
tislelizumab
46
Blood Specimen Collection
43
Cetuximab
35
Taxes
34
Platinum
33
Injections
33
Biopsy
33
Standard of Care
32
Immunoglobulin G
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interleukin-15
×
Thoracic
×
1 year
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled